Earlier this month, the FDA approved the once-daily oral drug Tradjenta (Boehringer Ingelheim and Eli Lilly’s linagliptin) for type 2 diabetes. Tradjenta belongs to the...
Diabetes Drug News
Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.
Metformin Insulin SGLT-2 GLP-1 DPP-4 Combo drugs Sulfonylureas TZDs
24 readers recommended
Obesity expert Dr. Lee Kaplan of Massachusetts General Hospital tells us how we may be able to bypass the bypass…
14 readers recommended
In mid-November, Santarus Inc. announced the launch of Cycloset, a novel, weight-neutral, glucose-lowering drug for type 2 diabetes. Cycloset is a quick-release...
27 readers recommended
Puzzled by the recent FDA decisions? Dr. Sanjay Kaul discusses the regulatory environment for diabetes and obesity medications.
41 readers recommended
Former ADA President Dr. John Buse offers a take on the ADA and FDA and weighs in on the current regulatory environment and healthcare reform.
29 readers recommended
Medical technology manufacturer Valeritas announced earlier this month that it received FDA clearance to market its V-Go Disposable Insulin Delivery Device, which...
33 readers recommended
In a recent study, Novo Nordisk's next-generation basal insulin degludec was found to cause less hypoglycemia than Lantus. In early May, Novo Nordisk announced the...
19 readers recommended
Novo Nordisk continues to make headway in the development of Degludec and DegludecPlus, the company’s two new “next-generation” insulins. The company recently announced...
43 readers recommended
In early November, Kombiglyze, a pill combining DPP-4 inhibitor Onglyza and metformin, was approved by the FDA for type 2 diabetes. Onglyza was approved in July 2010...
26 readers recommended
In mid-April, the European Medicine Agency's Committee for Medicinal Products for Human Use (a committee called the "CHMP") recommended that Amylin/Lilly/Alkermes' once-...
31 readers recommended
The FDA’s decision on Bydureon was a shocker. We break down this decision and discuss why we view it as such a disappointment.
34 readers recommended
In late 2010, Merck announced that it had acquired SmartCells, a small Massachusetts-based company that is developing a smart insulin product aptly named SmartInsulin...
23 readers recommended
People with diabetes are at significantly increased risk for kidney impairment or kidney failure. Kidney disease can complicate the treatment of type 2 diabetes because...
30 readers recommended
Type 1s and GLP-1s? diaTribe Editor-In-Chief Kelly Close tries Victoza and shares her remarkable results.
50 readers recommended
Earlier this month, Eli Lilly and the German pharmaceutical Boehringer Ingelheim (BI) announced a major partnership to co-develop and co-commercialize several of their...
11 readers recommended
In late July, pharmacy benefit managers (PBMs) Express Scripts and Medco Health Solutions announced their plans to merge. As background, PBMs process prescriptions for...
28 readers recommended
In late June, the European Medicines Agency (EMA) approved Amylin/Eli Lilly/Alkermes’ once-weekly injectable drug Bydureon for type 2 diabetes. We’ve been waiting for...
25 readers recommended
In October, Novo Nordisk announced that it had submitted its two new “next-generation” insulin products for approval in both the US and Europe (and Japan to follow soon...
25 readers recommended
In June, Insulet announced the acquisition of Neighborhood Diabetes, a medical equipment distributor that specializes in consumer sales of diabetes supplies. The company...
44 readers recommended
Over the past several years, the use of GLP-1 drugs (such as Byetta and Victoza) together with basal insulins (such as Lantus and Levemir) as a treatment for type 2...